Products for Research Use Only
RegisterLogin

Capivasertib

CAT: 0013-GTR19173092-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19173092-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Capivasertib (AZD5363) is an orally active, pan-AKT inhibitor targeting Akt1, Akt2, and Akt3 with low nanomolar potency. It demonstrates antitumor efficacy in preclinical models of breast cancer and is widely used in research exploring AKT signaling in oncology, supported by both in vitro and in vivo studies.
CAS Number
1143532-39-1
Product Name Alternative
Inhibitor, inhibit, mTOR (p70S6K), Akt, AZD 5363, Autophagy, AZD5363, AZD-5363, Akt1, Akt2, Akt3, Capivasertib, Protein kinase B, PKB, PKA
Field of Research
Cell Biology, Signal Transduction
Purity
97.59% (May vary between batches)
Solubility
DMSO:130 mg/mL (303.09 mM) ; Ethanol:1 mg/mL (2.33 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:8 mg/mL (18.65 mM) ; H2O:Insoluble
Smiles
NC1 (CCN (CC1) c1ncnc2[nH]ccc12) C (=O) N[C@@H] (CCO) c1ccc (Cl) cc1
Molecular Formula
C21H25ClN6O2
Molecular Weight
428.92
References & Citations
Petros A Tyrakis 1, Domen Kampjut 1, Georgina F Steele 1, H Jonathan G Lindström 1, Deborah Chirnomas 1, Benjamin D Hopkins 2, Marcus D Goncalves 3, Siddhartha Mukherjee 4, Lewis C Cantley 5, Oliver D K Maddocks 6 Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models Br J Cancer ., (2025)
Pubmed id
40360883
Storage Conditions
-20°C
Notes
For research use only.

Alternative Products

CatalogName
BUP12094-01Capivasertib
C13128-100mgCapivasertib (AZD5363)
CS-O-59072Capivasertib-d4
HY-15431R-01Capivasertib (Standard)
TYD-02708-01(R) -Capivasertib
AR-C05983-01Capivasertib-d6
CS-O-64825Capivasertib-d5
CS-O-60041N-Nitroso Capivasertib
RM-C017603-01Capivasertib Impurity 3
RM-C017604-01Capivasertib Impurity 4

Popular Products